{"classes":[{"categories":[{"measurements":[{"comment":"The upper bound of the 95% confidence interval was not estimable due to insufficient number of participants with events at the tail of the Kaplan-Meier curve.","groupId":"OG000","lowerLimit":"3.0","upperLimit":"NA","value":"5.6"},{"comment":"The upper bound of the 95% confidence interval was not estimable due to insufficient number of participants with events at the tail of the Kaplan-Meier curve.","groupId":"OG001","lowerLimit":"3.5","upperLimit":"NA","value":"9.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Duration of response was defined as the interval from the date of the first documentation of tumor response (CR or PR) that was subsequently confirmed by investigator assessment to the date of first occurrence of radiographic disease progression based on RECIST 1.1 or RANO criteria or death due to any cause, whichever occurs earlier. DOR was estimated using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Adult participants (≥ 18 years) were administered Tovorafenib 600 mg orally (PO) once weekly (QW).","id":"OG000","title":"Melanoma Cohort"},{"description":"Adult participants (≥ 18 years) were administered Tovorafenib 600 mg PO QW.","id":"OG001","title":"Tissue Agnostic Cohort"}],"paramType":"MEDIAN","populationDescription":"Participants in the Efficacy Analysis Set who have a confirmed response of CR or PR.","reportingStatus":"POSTED","timeFrame":"Up to 23 months","title":"Duration of Response (DOR) in Participants With Best Overall Response","type":"SECONDARY","unitOfMeasure":"Months"}